Computational and experimental advances in drug repositioning for accelerated therapeutic stratification.
暂无分享,去创建一个
[1] Van V. Brantner,et al. Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.
[2] Stephen T. C. Wong,et al. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. , 2012, Cancer research.
[3] David Jou,et al. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). , 2011, Journal of medicinal chemistry.
[4] Hugh A Barton,et al. Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond , 2013, Expert opinion on drug metabolism & toxicology.
[5] Y. Ff. New drugs for old uses and new uses for old drugs , 1959 .
[6] Pankaj Agarwal,et al. Systematic Drug Repositioning Based on Clinical Side-Effects , 2011, PloS one.
[7] F. Iorio,et al. Transcriptional data: a new gateway to drug repositioning? , 2013, Drug discovery today.
[8] H. Katus,et al. Risk stratification and therapeutic decision making in patients with acute coronary syndrome--the role of cardiac troponin T. , 1999, Clinical chemistry and laboratory medicine.
[9] H. Katus,et al. Risk Stratification and Therapeutic Decision Making in Patients with Acute Coronary Syndromes the Role of Cardiac Troponin T , 1999 .
[10] E Harris. Antidepressants: Old Drugs, New Uses , 1981, The American journal of nursing.
[11] J. Y. Wick. Psychiatric promise: old drugs, new uses. , 1993, American pharmacy.
[12] J. Cano,et al. Human hepatocytes as a keyin vitro model to improve preclinical drug development , 1990, European Journal of Drug Metabolism and Pharmacokinetics.
[13] T. Scior,et al. Application of drug repositioning strategy to TOFISOPAM. , 2008, Current medicinal chemistry.
[14] Yang Liu,et al. VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies , 2013, Nucleic Acids Res..
[15] A. Butte,et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. , 2013, Cancer discovery.
[16] D. Altshuler,et al. Validating therapeutic targets through human genetics , 2013, Nature Reviews Drug Discovery.
[17] R. Weinshilboum,et al. Pharmacogenetics and pharmacogenomics: development, science, and translation. , 2006, Annual review of genomics and human genetics.
[18] A. Chiang,et al. Data‐Driven Methods to Discover Molecular Determinants of Serious Adverse Drug Events , 2009, Clinical pharmacology and therapeutics.
[19] Jianghong An,et al. A large-scale computational approach to drug repositioning. , 2006, Genome informatics. International Conference on Genome Informatics.
[20] C. Chong,et al. New uses for old drugs , 2007, Nature.
[21] Hao Ye,et al. Construction of Drug Network Based on Side Effects and Its Application for Drug Repositioning , 2014, PloS one.
[22] R. Virmani,et al. Vascular healing in drug-eluting stents: differential drug-associated response of limus-eluting stents in a preclinical model of stent implantation. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[23] J. DiMasi. New drug development in the United States from 1963 to 1999 , 2001, Clinical pharmacology and therapeutics.
[24] Julio Saez-Rodriguez,et al. Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties , 2012, PloS one.
[25] Joel Dudley,et al. Network-Based Elucidation of Human Disease Similarities Reveals Common Functional Modules Enriched for Pluripotent Drug Targets , 2010, PLoS Comput. Biol..
[26] Francis S. Collins,et al. Mining for therapeutic gold , 2011, Nature Reviews Drug Discovery.
[27] B. Gallagher,et al. New therapeutic uses for an old family of drugs: travels of a dental researcher from the lab to the university's office of technology transfer and beyond. , 1996, Technology and health care : official journal of the European Society for Engineering and Medicine.
[28] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[29] E. Snitkin,et al. Genome-wide prioritization of disease genes and identification of disease-disease associations from an integrated human functional linkage network , 2009, Genome Biology.
[30] W. Bisson. Drug repurposing in chemical genomics: can we learn from the past to improve the future? , 2012, Current topics in medicinal chemistry.
[31] F F YONKMAN. [New drugs for old uses and new uses for old drugs]. , 1959, Journal - Michigan State Medical Society.
[32] Philip E. Bourne,et al. PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..
[33] Joel Dudley,et al. Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..
[34] K. Dolinski,et al. Use and misuse of the gene ontology annotations , 2008, Nature Reviews Genetics.
[35] R. Tagliaferri,et al. Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.
[36] Louis A Tartaglia. Complementary new approaches enable repositioning of failed drug candidates , 2006, Expert opinion on investigational drugs.
[37] Richard B. Smith,et al. Repositioned drugs: integrating intellectual property and regulatory strategies , 2011 .
[38] Michael Q. Zhang,et al. Network-based global inference of human disease genes , 2008, Molecular systems biology.
[39] Deepak K Rajpal,et al. Applications of Connectivity Map in drug discovery and development. , 2012, Drug discovery today.
[40] X. Chen,et al. From phenotype to gene: Detecting disease‐specific gene functional modules via a text‐based human disease phenotype network construction , 2010, FEBS letters.
[41] Winston Haynes,et al. Integrative Analysis of Longitudinal Metabolomics Data from a Personal Multi-Omics Profile , 2013, Metabolites.
[42] J. D. Kleinke. The price of progress: prescription drugs in the health care market. , 2001, Health affairs.
[43] Asher Mullard,et al. Drug repurposing programmes get lift off , 2012, Nature Reviews Drug Discovery.
[44] Tao Xu,et al. Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways , 2013, PLoS Comput. Biol..
[45] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[46] Philip E. Bourne,et al. Anti-Infectious Drug Repurposing Using an Integrated Chemical Genomics and Structural Systems Biology Approach , 2013, Pacific Symposium on Biocomputing.
[47] Walter Kolch,et al. Systems biology embedded target validation: improving efficacy in drug discovery , 2022 .
[48] A. Lohse,et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation , 2012, Hepatology.
[49] Steven J. M. Jones,et al. A Computational Approach to Finding Novel Targets for Existing Drugs , 2011, PLoS Comput. Biol..
[50] Guanghui Hu,et al. Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.
[51] David C. McPhie. Old drugs, new uses: solving a Hatch-Waxman patent predicament. , 2004, Food and drug law journal.
[52] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[53] Fan Yang,et al. Drug-target interaction prediction by integrating chemical, genomic, functional and pharmacological data. , 2013, Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.
[54] Kelly Chibale,et al. Drug repositioning in the treatment of malaria and TB. , 2011, Future medicinal chemistry.
[55] Y. Moreau,et al. Finding the targets of a drug by integration of gene expression data with a protein interaction network. , 2013, Molecular bioSystems.
[56] Alexander E. Ivliev,et al. Drug Target Prediction and Repositioning Using an Integrated Network-Based Approach , 2013, PloS one.
[57] Ola Spjuth,et al. Automated QuantMap for rapid quantitative molecular network topology analysis , 2013, Bioinform..
[58] Michal Magid-Slav,et al. Identification of Common Biological Pathways and Drug Targets Across Multiple Respiratory Viruses Based on Human Host Gene Expression Analysis , 2012, PloS one.
[59] Nikolaus Forgó,et al. Using EHRs to design drug repositioning trials: A devolved approach to data protection , 2014 .
[60] S. Rees,et al. Principles of early drug discovery , 2011, British journal of pharmacology.
[61] Jeffrey Aubé,et al. Drug repurposing and the medicinal chemist. , 2012, ACS medicinal chemistry letters.
[62] Kenneth Jung,et al. Automated Detection of Systematic Off-label Drug Use in Free Text of Electronic Medical Records , 2013, AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science.
[63] Pankaj Agarwal,et al. Evaluation of Analytical Methods for Connectivity Map Data , 2012, Pacific Symposium on Biocomputing.
[64] Khader Shameer,et al. Functional repertoire, molecular pathways and diseases associated with 3D domain swapping in the human proteome , 2012, Journal of Clinical Bioinformatics.
[65] Joel Dudley,et al. Translational Bioinformatics Approaches to Drug Development. , 2013, Advances in wound care.
[66] L. Cardon,et al. Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.
[67] Hong-yu Zhang,et al. Rational drug repositioning by medical genetics , 2013, Nature Biotechnology.
[68] Joel T Dudley,et al. Biomarker and drug discovery for gastroenterology through translational bioinformatics. , 2010, Gastroenterology.
[69] Yadi Zhou,et al. Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods. , 2012, Molecular bioSystems.
[70] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[71] L Lasagna,et al. New drug development in the United States from 1963 to 1990 , 1991, Clinical pharmacology and therapeutics.
[72] A. Barabasi,et al. The human disease network , 2007, Proceedings of the National Academy of Sciences.
[73] J. An,et al. Structure-based virtual screening of chemical libraries for drug discovery. , 2006, Current opinion in chemical biology.
[74] A. Butte,et al. Network Medicine in Disease Analysis and Therapeutics , 2013, Clinical pharmacology and therapeutics.
[75] Y. Quan,et al. Medical genetic inspirations for anticancer drug repurposing. , 2014, Trends in pharmacological sciences.
[76] M. Schroeder,et al. Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network. , 2012, Integrative biology : quantitative biosciences from nano to macro.
[77] Cui Tao,et al. Exploring the Pharmacogenomics Knowledge Base (PharmGKB) for Repositioning Breast Cancer Drugs by Leveraging Web Ontology Language (OWL) and Cheminformatics Approaches , 2013, Pacific Symposium on Biocomputing.
[78] P. Sanseau,et al. Computational Drug Repositioning: From Data to Therapeutics , 2013, Clinical pharmacology and therapeutics.
[79] Nonprofit disease groups earmark grants for drug repositioning , 2011, Nature Medicine.
[80] Mårten Fryknäs,et al. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer , 2013, Journal of Cancer Research and Clinical Oncology.
[81] Albert-László Barabási,et al. A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..
[82] Brian K. Shoichet,et al. Virtual screening of chemical libraries , 2004, Nature.
[83] C. K. Cain,et al. Annual Reports in Medicinal Chemistry , 2002 .
[84] R. Sharan,et al. PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.
[85] Alexander A. Morgan,et al. Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.
[86] Y Z Chen,et al. Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery. , 2013, Current medicinal chemistry.
[87] Ryen W. White,et al. Web-scale pharmacovigilance: listening to signals from the crowd , 2013, J. Am. Medical Informatics Assoc..
[88] Alexander A. Morgan,et al. Clinical assessment incorporating a personal genome , 2010, The Lancet.
[89] Lokesh P. Tripathi,et al. TargetMine, an Integrated Data Warehouse for Candidate Gene Prioritisation and Target Discovery , 2011, PloS one.
[90] Guangji Wang,et al. Prediction of human pharmacokinetics from preclinical information of rhein, an antidiabetic nephropathy drug, using a physiologically based pharmacokinetic model. , 2014, Basic & clinical pharmacology & toxicology.
[91] Steven J. M. Jones,et al. Drug repositioning for personalized medicine , 2012, Genome Medicine.
[92] Philip E. Bourne,et al. Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis , 2009, PLoS Comput. Biol..
[93] Joel Dudley,et al. Identification of Discriminating Biomarkers for Human Disease Using Integrative Network Biology , 2008, Pacific Symposium on Biocomputing.
[94] Winston A Hide,et al. Big data: The future of biocuration , 2008, Nature.
[95] A. Brüning. Targeting the off-targets: a computational bioinformatics approach to understanding the polypharmacology of nelfinavir , 2011, Expert review of clinical pharmacology.
[96] Claus Christiansen,et al. Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioning. , 2011, Drug discovery today.
[97] Krin A. Kay,et al. The implications of human metabolic network topology for disease comorbidity , 2008, Proceedings of the National Academy of Sciences.
[98] Stephen W Michnick,et al. The connectivity map , 2006, Nature chemical biology.
[99] K. Tsuda,et al. Mining Significant Substructure Pairs for Interpreting Polypharmacology in Drug-Target Network , 2011, PloS one.
[100] Jun Zou,et al. Advanced Systems Biology Methods in Drug Discovery and Translational Biomedicine , 2013, BioMed research international.
[101] R. Adolph. Old drugs with new uses. Colchicine for treatment of recurrent pericarditis. , 1990, Circulation.
[102] Alexander A. Morgan,et al. Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.
[103] Dima Kozakov,et al. Hot Spot Analysis for Driving the Development of Hits into Leads in Fragment-Based Drug Discovery , 2012, J. Chem. Inf. Model..
[104] U. Wolfrum,et al. Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease. , 2006, Experimental eye research.
[105] Paolo Massimo Buscema,et al. The semantic connectivity map: an adapting self-organising knowledge discovery method in data bases. Experience in gastro-oesophageal reflux disease , 2008, Int. J. Data Min. Bioinform..
[106] M. DePamphilis,et al. HUMAN DISEASE , 1957, The Ulster Medical Journal.
[107] Brendan J. Quinn,et al. Repositioning metformin for cancer prevention and treatment , 2013, Trends in Endocrinology & Metabolism.
[108] A. Butte,et al. Drug Discovery in a Multidimensional World: Systems, Patterns, and Networks , 2010, Journal of cardiovascular translational research.
[109] Jean Lu,et al. Functional Module Connectivity Map (FMCM): A Framework for Searching Repurposed Drug Compounds for Systems Treatment of Cancer and an Application to Colorectal Adenocarcinoma , 2014, PloS one.
[110] Susana Murteira,et al. Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature , 2013, Journal of market access & health policy.
[111] K. Chibale,et al. Recent developments in rationally designed multitarget antiprotozoan agents. , 2013, Current medicinal chemistry.
[112] Luonan Chen,et al. Network-based drug repositioning. , 2013, Molecular bioSystems.
[113] Scott Parker,et al. Patenting personalized medicines in the UK, Europe and USA. , 2014, Pharmaceutical patent analyst.
[114] M. X. Fernandes,et al. New Uses for Old Drugs: Pharmacophore‐Based Screening for the Discovery of P‐Glycoprotein Inhibitors , 2011, Chemical biology & drug design.
[115] Justin Lamb,et al. The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.
[116] Ralph A. Tripp,et al. siRNA Genome Screening Approaches to Therapeutic Drug Repositioning , 2013, Pharmaceuticals.
[117] Clara Campas,et al. Drug repositioning summit: finding new routes to success. , 2009, Drug news & perspectives.
[118] Xiaowei Xu,et al. Investigating drug repositioning opportunities in FDA drug labels through topic modeling , 2012, BMC Bioinformatics.
[119] Sridhar Ramaswamy,et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..
[120] E. Tobinick. The value of drug repositioning in the current pharmaceutical market. , 2009, Drug news & perspectives.
[121] Y Z Chen,et al. Virtual screening methods as tools for drug lead discovery from large chemical libraries. , 2012, Current medicinal chemistry.
[122] R. D'Amato,et al. Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[123] K. Thor,et al. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. , 1995, The Journal of pharmacology and experimental therapeutics.
[124] Nigam H. Shah,et al. Automated Detection of Off-Label Drug Use , 2014, PloS one.
[125] Yadi Zhou,et al. Prediction of Chemical-Protein Interactions Network with Weighted Network-Based Inference Method , 2012, PloS one.
[126] Peng Zhan,et al. "Old friends in new guise": exploiting privileged structures for scaffold re-evolution/refining. , 2014, Combinatorial chemistry & high throughput screening.
[127] Cheng Zhu,et al. Drug repositioning for orphan diseases , 2011, Briefings Bioinform..
[128] Natalia Novac,et al. Challenges and opportunities of drug repositioning. , 2013, Trends in pharmacological sciences.
[129] G. Kaplan,et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes , 1991, The Journal of experimental medicine.
[130] Robert Gentleman,et al. Querying Genomic Databases: Refining the Connectivity Map , 2012, Statistical applications in genetics and molecular biology.
[131] S. Rajkumar,et al. The high cost of cancer drugs and what we can do about it. , 2012, Mayo Clinic proceedings.
[132] M. Ramanathan,et al. Network‐Based Approaches in Drug Discovery and Early Development , 2013, Clinical pharmacology and therapeutics.
[133] Ivan Molineris,et al. Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters (CAGCs) , 2013, BMC Bioinformatics.
[134] Mathewson Ma. New uses for old drugs: vasodilators (CEU home study). , 1982 .
[135] Noor B. Dawany,et al. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases , 2012, Inflammatory bowel diseases.
[136] T. Enomoto,et al. Therapeutic strategies in epithelial ovarian cancer , 2012, Journal of Experimental & Clinical Cancer Research.
[137] A J Atkinson,et al. Panel on public service drugs and new uses for old drugs , 1975, Clinical pharmacology and therapeutics.
[138] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[139] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[140] Patricia McGrath,et al. Zebrafish: a preclinical model for drug screening. , 2002, Assay and drug development technologies.
[141] Hugo Y. K. Lam,et al. Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.
[142] Giorgio Valentini,et al. Network-Based Drug Ranking and Repositioning with Respect to DrugBank Therapeutic Categories , 2013, IEEE/ACM Transactions on Computational Biology and Bioinformatics.
[143] Ramaiah Muthyala,et al. Orphan/rare drug discovery through drug repositioning , 2011 .
[144] Brad T. Sherman,et al. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.
[145] Yong Wang,et al. Network predicting drug's anatomical therapeutic chemical code , 2013, Bioinform..
[146] New ways to take old drugs. , 1998, STEP perspective.